The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed viral claims that Camosunate, a widely used antimalarial drug, has been banned in Nigeria.
The agency described the reports circulating on social media as false, insisting that neither Camosunate nor medicines containing the artesunate-amodiaquine combination had been banned.
In a statement issued on Saturday and signed by its Director-General, Prof. Mojisola Adeyeye, NAFDAC urged Nigerians to disregard the claims and stop spreading unverified information about the drug.
“The Agency clarifies that it has never banned Camosunate or medicines containing the artesunate-amodiaquine combination,” the statement said.
However, the agency acknowledged that some of the symptoms highlighted in the viral reports could be linked to known side effects of the medicine.
It listed nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, drowsiness and loss of appetite among the possible reactions associated with Camosunate.
“However, suspected adverse drug reactions should be reported to NAFDAC for proper assessment,” it added.
NAFDAC urged patients and healthcare professionals who notice unusual reactions after using the drug to report them through its Med Safety App, available on Android and iOS devices, or at the nearest NAFDAC office.
The agency also warned against spreading the alleged ban, particularly on social media, urging those who had already shared the claims to circulate its clarification through the same channels.
“NAFDAC urges the public to stop circulating the false claim,” the statement added.
The clarification follows widespread social media reports alleging that Camosunate had been banned in Nigeria over concerns about its reported adverse effects.
Don’t Miss Out! Join our WhatsApp Channel for instant news updates. Click here to join



